Headlines > Clinical Development
State of the market
Related topics: Clinical Development
Speakers
Mr Gareth Macdonald
Senior Editor
Outsourcing-Pharma.com
Mr Eric Bolesh
Cutting Edge Information
Cutting Edge Information
On average over half the cost of developing a new cancer drug is associated with work outsourced to contract research organisations (CRO), according to analysis by Cutting Edge Information. This finding, coupled with the pharmaceutical industry’s ever present desire for more efficient R&D spending, means that finding the right contractor and monitoring performance is more important than ever.
In his presentation Eric Bolesh will examine this issue and discuss the following: How pharmaceutical firms work successfully with CROs? What clinical work is contracted out to third parties? How is vendor performance measured?; and how, ultimately, is this information used to shape future sourcing strategies and drug development projects be that for a new treatment for cancer or for any other disease.
Copyright - Unless otherwise stated all contents of this web site are © 2013 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
All Webinars
  |
State of the marketOn average over half the cost of developing a new cancer drug is associated with... |
 |
Patient recruitment: improving access to patientsRecruiting patients is often, if not always, the most expensive and time consuming part of... |
 |
Managing strategic relationships in cancer trialsThe way drug companies work with CROs is evolving, with the emphasis shifting from the... |
Most Popular News
Key Industry Events
BioPharm America™ 2013—6th Annual International Partnering Conference
Boston, MA, USA / Conference
